Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective

Página do item simplificado
dc.citation.issue1
dc.citation.volume24
dc.contributor.authorCantu-Brito, Carlos
dc.contributor.authorSilva, Gisele Sampaio [UNIFESP]
dc.contributor.authorAmeriso, Sebastian F.
dc.coverageThousand Oaks
dc.date.accessioned2020-07-02T18:52:14Z
dc.date.available2020-07-02T18:52:14Z
dc.date.issued2018
dc.description.abstractAtrial fibrillation (AF) is a prominent risk factor for stroke and a leading cause of death and disability throughout Latin America. Contemporary evidence-based guidelines for the management of AF and stroke incorporate the use of practical and relatively simple scoring methods to estimate both stroke and bleeding risk, in order to assist in matching patients with appropriate interventions. This review examines consistencies and differences among guidelines for reducing stroke risk in patients with AF, assessing the role of user-friendly scoring methods to determine appropriate patients for anticoagulation and other treatment options. Current options include warfarin and direct oral anticoagulants such as dabigatran, rivaroxaban, apixaban, and edoxaban. These agents have been found to be superior or noninferior to standard vitamin K antagonist anticoagulation in large randomized trials. Potential benefits of these agents mainly include lower ischemic stroke rates, reduced intracranial bleeding, no need for regular monitoring, and fewer drug-drug and drug-food interactions. Expert opinions regarding clinical situations for which data are presently lacking, such as emergency bleeding and stroke in anticoagulated patients, are also provided. Enhanced attention and adherence to evidence-based guidelines are essential components for a strategy to reduce stroke morbidity and mortality across Latin America.en
dc.description.affiliationNatl Inst Med Sci & Nutr Salvador Zubiran, Dept Neurol, Mexico City, DF, Mexico
dc.description.affiliationUNIFESP Univ Fed Sao Paulo, Hosp Israelita Albert Einstein, Sao Paulo, Brazil
dc.description.affiliationFLENI, Neurol Res Inst, Buenos Aires, DF, Argentina
dc.description.affiliationUnifespUNIFESP Univ Fed Sao Paulo, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipBristol-Myers Squibb
dc.description.sponsorshipPfizer
dc.format.extent22-32
dc.identifierhttp://dx.doi.org/10.1177/1076029617734309
dc.identifier.citationClinical And Applied Thrombosis-Hemostasis. Thousand Oaks, v. 24, n. 1, p. 22-32, 2018.
dc.identifier.doi10.1177/1076029617734309
dc.identifier.fileWOS000417681500003.pdf
dc.identifier.issn1076-0296
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/53970
dc.identifier.wosWOS:000417681500003
dc.language.isoeng
dc.publisherSage Publications Inc
dc.relation.ispartofClinical And Applied Thrombosis-Hemostasis
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectevidence-based guidelinesen
dc.subjectLatin Americaen
dc.subjectnonvalvular atrial fibrillationen
dc.titleUse of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspectiveen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000417681500003.pdf
Tamanho:
316.87 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos